Too many people are put on lifelong levothyroxine for borderline TSH elevations or nonspecific symptoms, then never reassessed, yet trials show little benefit for most with subclinical hypothyroidism and risks from overtreatment like a-fib and bone loss. We need to normalize “deprescribing” thyroid hormone when it was started for borderline labs, low doses, or no clear diagnosis, and routinely see if patients can come off instead of renewing forever.
jamanetwork.com/journals/jam…